• 제목/요약/키워드: Vaccines

Search Result 798, Processing Time 0.031 seconds

Vaccines for Diarrheal Diseases (위장관염에 대한 백신)

  • Park, Su Eun
    • Pediatric Infection and Vaccine
    • /
    • v.16 no.2
    • /
    • pp.115-122
    • /
    • 2009
  • Diarrhea is one of the most common causes of morbidity and mortality in children worldwide. Rotavirus is the most common cause of infectious diarrhea both in developed and developing countries. However, bacterial causes such as Salmonella typhi and Vibrio cholerae still play an important role in developing countries. Newly developed vaccines for rotavirus, S. typhi, and V. choleae are highly immunogenic and safe in children.

  • PDF

Output traits in crop plants: Nutrients and pharmaceuticals

  • Yu, Ju-Kyung
    • Journal of Plant Biotechnology
    • /
    • v.37 no.1
    • /
    • pp.67-71
    • /
    • 2010
  • Output traits centered on improved plant-based products will find their way to consumers in such ways as nutritionally enhanced foods, therapeutic proteins for disease treatment and vaccines, bio-industrial products, modified oil quality and biofuels. Significant progress in biotechnology has occurred over the last several decades. The importance of output traits development and production using biotechnology will impact not only agribusiness, but also pharmaceutical and food industries. The objective of this paper is to review briefly the current status of output traits development in crop plants using nutrients and pharmaceuticals as examples.

An Animal Model to Evaluate the Protective Efficacy of Haemophilus influenzae Type b Conjugate Vaccines

  • Kim Hyun Sung;Yoo Tae Hyeon;Jang Yang Suk;Kim Hun;Park Jin Yong;Hur Byung Ki;Ryu Yeon Woo;Kim Jong Su
    • Biotechnology and Bioprocess Engineering:BBE
    • /
    • v.9 no.6
    • /
    • pp.490-494
    • /
    • 2004
  • An efficacy test of PRP (polyribosylribitol phosphate)-TT (Tetanus toxoid) conjugate vaccines was carried out using BALB/c mice as an animal model by inoculating Haemophilus in­fluenzae type b (Hib) with a virulence enhancement factor (VEF). Three administrations of the conjugate vaccines at 2-week intervals elicited a significantly high level of PRP antibodies (P>0.0001). The protective activity of the PRP immunization was challenged with either Hib with iron dextran (Hib/) or with a combination of mucin and hemoglobin (Hibmh) as a VEF. The me­dium lethal dose $(LD_{50})$ for Hibmh and Hibiwas measured as 10 CFU (Colony Forming Unit) and $2.5{\times}10^{8}$ CFU respectively. Each immunized animal was challenged with five or ten times the $LD_{50}$ level of bacteria with a VEF. A significant difference in mortality between the immunized and control mice (P> 0.01) was observed with the Hibmh challenge inoculation but not with the Hibi challenge inoculation. These results show that a combination of mucin and hemoglobin was able to enhance the virulence of Hib in BALB/c mice to cause a lethal infection, thus suggesting that BALB/c mice introduced to this method can be an effective model animal for testing the protective efficacy of H. influenzae conjugate vaccines.

Evaluation of stability and potency of live attenuated rinderpest vaccine of lapinized-avianized tissue culture strain origin for the establishment of expiration period (가토화·계태화 우역 생백신의 유효기간 설정을 위한 안정성 및 효능 평가)

  • Yeh, Jung-Yong;Kim, Hyun-Ju;Nah, Jin-Ju;Park, Jee-Yong;Lee, Ji-Hye;Seo, Hyun-Ji;Kweon, Chang-Hee;Cho, In-Soo;Moon, Jin-San
    • Korean Journal of Veterinary Research
    • /
    • v.49 no.3
    • /
    • pp.201-205
    • /
    • 2009
  • In this study, we evaluated the stability and potency of live attenuated rinderpest vaccines of lapinized-avianized tissue culture strain origin, which had been produced annually from 2005 to 2008. When immune responses to the vaccines were evaluated using two Holstein calves weighing 100~150 kg, neutralizing antibody titer of 1 : 16 was induced at 21 days post vaccination. When calves were also inoculated with vaccines lots that had been stored for 39 months at ${4^{\circ}C}$, same level of antibody titer was observed. Using the virus titer test, we found that all batches of the vaccine that had been kept for 3, 10, 15, 22, 27, 34, 39, and 45 months showed no significant loss of titers, and fulfilled the requirement necessary ($\geq$ 3 $logTCID_50$) to be used as the national rinderpest vaccine reserve in Korea. In this study, we demonstrated that stability and potency of the rinderpest vaccines were maintained over three years when kept at ${4^{\circ}C}$ storage. This indicates that it maybe feasible to extend the expiration period of this vaccine from one year to three years.

Factors Affecting Vaccination Status of Female Adolescents Subject to the Korean National HPV Immunization Program: Focusing on Mothers' HPV Knowledge and Heath Beliefs of HPV Vaccines

  • Park, Seungmi;Jang, Insun;Lee, Jung Lim;Kim, Youngji
    • Journal of the Korean Society of School Health
    • /
    • v.33 no.1
    • /
    • pp.58-66
    • /
    • 2020
  • Purpose: HPV vaccination is important for the prevention of cervical cancer and genital warts and it is recommended that females be vaccinated against HPV before having sexual contact. Although the national HPV immunization has recently started in Korea, the vaccination rate is still not high. This is a relevant study attempting to investigate the factors affecting the vaccination status of female adolescents in the target age groups focusing on mothers' knowledge and health beliefs of HPV vaccines. Methods: Participants were 206 mothers who had daughters at the target age for the national HPV vaccination program living in a metropolitan city. Data were collected using a self-reported questionnaire about HPV knowledge and health beliefs of HPV vaccines, consisting of perceived susceptibility seriousness, benefits, barriers, and cues to action. Results: The participants' knowledge of HPV was significantly correlated with the overall health beliefs. The factors influencing mothers regarding the HPV vaccination status of their adolescent daughters were found to be perceived barriers, advice on vaccination from medical staff, and perceived benefits. Conclusion: There is a need to organize subject-specific education programs focusing on correcting misinformation about the side effects and benefits of HPV vaccines. When operating education programs, it is recommended that participants include both students and their parents, that various approaches be implemented such as formal health classes, home correspondence and online education, and that medical personnel be also involved as education providers.

Production of Recombinant Human Papillomavirus Type 52 L1 Protein in Hansenula polymorpha Formed Virus-Like Particles

  • Liu, Cunbao;Yao, Yufeng;Yang, Xu;Bai, Hongmei;Huang, Weiwei;Xia, Ye;Ma, Yanbing
    • Journal of Microbiology and Biotechnology
    • /
    • v.25 no.6
    • /
    • pp.936-940
    • /
    • 2015
  • Human papillomavirus (HPV) type 52 is a high-risk HPV responsible for cervical cancer. HPV type 52 is common around the world and is the most common in some Asian regions. The available prophylactic HPV vaccines protect only from HPV types 16 and 18. Supplementing economical vaccines that target HPV type 52 may satisfactorily complement available prophylactic vaccines. A codon-adapted HPV 52 L1 gene was expressed in the methylotrophic yeast Hansenula polymorpha, which is used as an industrial platform for economical hepatitis B surface antigen particle production in China. We found that the recombinant proteins produced in this expression system could form virus-like particles (VLPs) with diameters of approximately 50 nm. This study suggests that the HPV 52 VLPs produced in this platform may satisfactorily complement available prophylactic vaccines in fighting against HPVs prevalent in Asia.

Recommended immunization schedule for children and adolescents: Immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015

  • Kim, Jong-Hyun;Choi, Eun Hwa;Park, Su Eun;Kim, Yae-Jean;Jo, Dae Sun;Kim, Yun-Kyung;Eun, ByungWook;Lee, Jina;Lee, Soo-Young;Lee, Hyunju;Kim, Ki Hwan;Kim, Kyung-Hyo
    • Clinical and Experimental Pediatrics
    • /
    • v.59 no.12
    • /
    • pp.461-465
    • /
    • 2016
  • This report includes the recommended immunization schedule table for children and adolescents based on the 8th (2015) and revised 7th (2012) Immunization Guidelines released by the Committee on Infectious Diseases of the Korean Pediatric Society (KPS). Notable revised recommendations include: reorganization of the immunization table with a list of vaccines on the vertical axis and the corresponding age on the horizontal axis; reflecting the inclusion of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine, and hepatitis A vaccine into the National Immunization Program since 2012; addition of general recommendations for 2 new Japanese encephalitis (JE) vaccines and their interchangeability with existing JE vaccines; addition of general recommendations for quadrivalent meningococcal conjugate vaccines and scope of the recommended targets for vaccination; and emphasizing catch-up immunization of Tdap vaccine. Detailed recommendations for each vaccine may be obtained from the full KPS 8th Immunization Guidelines.

Protection of Mice Against Pandemic H1N1 Influenza Virus Challenge After Immunization with Baculovirus-Expressed Stabilizing Peptide Fusion Hemagglutinin Protein

  • Yang, Eunji;Cho, Yonggeun;Choi, Jung-ah;Choi, YoungJoo;Park, Pil-Gu;Park, Eunsun;Lee, Choong Hwan;Lee, Hyeja;Kim, Jongsun;Lee, Jae Myun;Song, Manki
    • Journal of Microbiology and Biotechnology
    • /
    • v.25 no.2
    • /
    • pp.280-287
    • /
    • 2015
  • Current influenza vaccines are produced in embryonated chicken eggs. However, egg-based vaccines have various problems. To address these problems, recombinant protein vaccines have been developed as new vaccine candidates. Unfortunately, recombinant proteins frequently encounter aggregation and low stability during their biogenesis. It has been previously demonstrated that recombinantly expressed proteins can be greatly stabilized with high solubility by fusing stabilizing peptide (SP) derived from the C-terminal acidic tail of human synuclein (ATS). To investigate whether SP fusion proteins can induce protective immunity in mice, we produced influenza HA and SP fusion protein using a baculovirus expression system. In in vitro tests, SP-fused recombinant HA1 (SP-rHA1) was shown to be more stable than recombinant HA1 (rHA1). Mice were immunized intramuscularly with baculovirus-expressed rHA1 protein or SP-rHA1 protein ($2{\mu}g/mouse$) formulated with aluminum hydroxide. Antibody responses were determined by ELISA and hemagglutination inhibition assay. We observed that SP-rHA1 immunization elicited HA-specific antibody responses that were comparable to rHA1 immunization. These results indicate that fusion of SP to rHA1 does not negatively affect the immunogenicity of the vaccine candidate. Therefore, it is possible to apply SP fusion technology to develop stable recombinant protein vaccines with high solubility.

Evolving Problem Analyses of Recent Marek's Disease (최근 진화하는 마렉병의 원인 분석)

  • Jang, H.K.;Park, Y.M.;Cha, S.Y.;Park, J.B.
    • Korean Journal of Poultry Science
    • /
    • v.34 no.4
    • /
    • pp.301-318
    • /
    • 2007
  • Marek's disease (MD) is a highly contagious lymphoproliferative disease of poultry caused by the oncogenic herpesvirus designated Marek's disease virus (MDV). MD has a worldwide distribution and is thought to cause an annual loss over US$ one billion to the poultry industry. Originally described as a paralytic disease, today MD is mostly manifested as an acute disease with tumors in multiple visceral organs. MD is controlled essentially by the widespread use of live vaccines administered either in ovo into 18-day-old embryos or into chicks immediately after they hatch. In spite of the success of the vaccines in reducing the losses from the disease in the last 30 years, MDV strains have shown continuous evolution in virulence acquiring the ability to overcome the immune responses induced by the vaccines. During this period, different generations of MD vaccines have been introduced to protect birds from the increasingly virulent MDV strains. However, the virus will be countered each new vaccine strategy with ever more virulent strains. In spite of this concern, currently field problem from MD is likely to be controled by strategy of using bivalent vaccine. But, potential risk factors for outbreak of MD are still remained in this condition. The major factors can be thought that improper handling and incorrect administration of the vaccine, infection prior to establishment of immunity, suppression of immune system by environmental stress and outbreaks of more virulent MDV strain by using vaccine and genetic resistance of host.

Enhancing immune responses to inactivated foot-and-mouth virus vaccine by a polysaccharide adjuvant of aqueous extracts from Artemisia rupestris L.

  • Wang, Danyang;Yang, Yu;Li, Jinyu;Wang, Bin;Zhang, Ailian
    • Journal of Veterinary Science
    • /
    • v.22 no.3
    • /
    • pp.30.1-30.15
    • /
    • 2021
  • Background: New-generation adjuvants for foot-and-mouth disease virus (FMDV) vaccines can improve the efficacy of existing vaccines. Chinese medicinal herb polysaccharide possesses better promoting effects. Objectives: In this study, the aqueous extract from Artemisia rupestris L. (AEAR), an immunoregulatory crude polysaccharide, was utilized as the adjuvant of inactivated FMDV vaccine to explore their immune regulation roles. Methods: The mice in each group were subcutaneously injected with different vaccine formulations containing inactivated FMDV antigen adjuvanted with three doses (low, medium, and high) of AEAR or AEAR with ISA-206 adjuvant for 2 times respectively in 1 and 14 days. The variations of antibody level, lymphocyte count, and cytokine secretion in 14 to 42 days after first vaccination were monitored. Then cytotoxic T lymphocyte (CTL) response and antibody duration were measured after the second vaccination. Results: AEAR significantly induced FMDV-specific antibody titers and lymphocyte activation. AEAR at a medium dose stimulated Th1/Th2-type response through interleukin-4 and interferon-γ secreted by CD4+ T cells. Effective T lymphocyte counts were significantly elevated by AEAR. Importantly, the efficient CTL response was remarkably provoked by AEAR. Furthermore, AEAR at a low dose and ISA-206 adjuvant also synergistically promoted immune responses more significantly in immunized mice than those injected with only ISA-206 adjuvant and the stable antibody duration without body weight loss was 6 months. Conclusions: These findings suggested that AEAR had potential utility as a polysaccharide adjuvant for FMDV vaccines.